Bolt Biotherapeutics reports 2026 annual meeting voting results

Bolt Biotherapeutics, Inc.

At June 10, 2026 annual meeting, 877,358 of 1,921,567 outstanding shares represented.
Directors William P. Quinn and Jakob Dupont elected as Class II members for three-year terms.
Quinn: 349,358 for, 52,117 withheld; Dupont: 377,163 for, 24,312 withheld; 475,883 broker non-votes each.
Ratification of PricewaterhouseCoopers as auditor for 2026: 768,336 for, 107,471 against, 1,551 abstain.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Bolt Biotherapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-10 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

The following director nominees were elected to serve as Class II members of the Company’s board of directors until the Company’s 2029 Annual Meeting of Stockholders, or until their respective successor is duly elected and qualified, or until their respective death, resignation or removal:

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Bolt Biotherapeutics, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026 at the 2026-06-10 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

The selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was ratified.

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-267487

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.